TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer
vaccine before chemotherapy to enhance immune responses, thus leading to a more effective
therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the
role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression
free survival (PFS) of subjects with HRPC.